Microbial Influences in Inflammatory Bowel Diseases

Gastroenterology

Volumn 134, Issue 2, 2008, Pages 577-594

  Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR; SMAD PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ARTICLE; BACTERIAL VIRULENCE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CROHN DISEASE; ENTERITIS; EPITHELIUM CELL; ESCHERICHIA COLI; GENETIC POLYMORPHISM; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; INTESTINE FLORA; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 38649115342     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.11.059     Document Type: Article

References (213)

1. Eckburg P.B., and Relman D.A. The role of microbes in Crohn's disease. Clin Infect Dis 44 (2007) 256-262
2. Strober W., Fuss I., and Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 117 (2007) 514-521
3. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 390-407
4. Xavier R.J., and Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007) 427-434
5. Sartor R.B., Blumberg R.S., Braun J., et al. CCFA microbial-host interactions workshop: highlights and key observations. Inflamm Bowel Dis 13 (2007) 600-619
6. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
7. Gill S.R., Pop M., Deboy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 312 (2006) 1355-1359
8. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006) 1027-1031
9. Frank D.N., St. Amand A.L., Feldman R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104 (2007) 13780-13785
10. Ley R.E., Peterson D.A., and Gordon J.I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124 (2006) 837-848
11. Hooper L.V., and Gordon J.I. Commensal host-bacterial relationships in the gut. Science 292 (2001) 1115-1118
12. Clavel T., and Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 13 (2007) 1153-1164
13. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006) 1022-1023
14. Pumbwe L., Skilbeck C.A., Nakano V., et al. Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of Bacteroides fragilis. Microb Pathog 43 (2007) 78-87
15. Strober W., Murray P.J., Kitani A., et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6 (2006) 9-20
16. Fukata M., Chen A., Klepper A., et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131 (2006) 862-877
17. Neish A.S., Gewirtz A.T., Zeng H., et al. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science 289 (2000) 1560-1563
18. Ruiz P.A., Shkoda A., Kim S.C., et al. IL-10 gene-deficient mice lack TGF-β/Smad-mediated TLR2 degradation and fail to inhibit proinflammatory gene expression in intestinal epithelial cells under conditions of chronic inflammation. Ann N Y Acad Sci 1072 (2006) 389-394
19. Kagnoff M.F., and Eckmann L. Epithelial cells as sensors for microbial infection. J Clin Invest 100 (1997) 6-10
20. Haller D., Holt L., Schwabe R.F., et al. Transforming growth factor-β 1 inhibits non-pathogenic gram-negative bacteria-induced NF-κB recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J Biol Chem 278 (2003) 23851-23860
21. EGFP mice reveal the critical role of TLR/NF-κB signaling in commensal bacteria-induced colitis. J Immunol 178 (2007) 6522-6532
22. Kitajima S., Morimoto M., Sagara E., et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp Anim 50 (2001) 387-395
23. Lee J., Mo J.H., Katakura K., et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 8 (2006) 1327-1336
24. Fukata M., Michelsen K.S., Eri R., et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288 (2005) G1055-G1065
25. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
26. Ohkawara T., Takeda H., Nishihira J., et al. Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice. Clin Exp Immunol 141 (2005) 412-421
27. Heimesaat M.M., Fischer A., Siegmund B., et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLos One 2 (2007) e662
28. Nenci A., Becker C., Wullaert A., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446 (2007) 557-561
29. Egan L.J., Eckmann L., Greten F.R., et al. IκB-kinase β-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 101 (2004) 2452-2457
30. Katakura K., Lee J., Rachmilewitz D., et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 115 (2005) 695-702
31. Zaph C., Troy A.E., Taylor B.C., et al. Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis. Nature 446 (2007) 552-556
32. Shibolet O., and Podolsky D.K. TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am J Physiol Gastrointest Liver Physiol 292 (2007) G1469-G1473
33. Zeng H., Wu H., Sloane V., et al. Flagellin/TLR5 responses in epithelia reveal intertwined activation of inflammatory and apoptotic pathways. Am J Physiol Gastrointest Liver Physiol 290 (2006) G96-G108
34. Kelly D., Campbell J.I., King T.P., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol 5 (2004) 104-112
35. Hooper L.V., Wong M.H., Thelin A., et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291 (2001) 881-884
36. Wehkamp J., Salzman N.H., Porter E., et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 102 (2005) 18129-18134
37. Kobayashi K.S., Chamaillard M., Ogura Y., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
38. Lala S., Ogura Y., Osborne C., et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 125 (2003) 47-57
39. Vora P., Youdim A., Thomas L.S., et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 173 (2004) 5398-5405
40. Lebeis S.L., Bommarius B., Parkos C.A., et al. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol 179 (2007) 566-577
41. Karrasch T., Steinbrecher K.A., Allard B., et al. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 207 (2006) 809-815
42. Cebra J.J. Influences of microbiota on intestinal immune system development. Am J Clin Nutr 69 (1999) S1046-S1051
43. Smythies L.E., Sellers M., Clements R.H., et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115 (2005) 66-75
44. Hoentjen F., Sartor R.B., Ozaki M., et al. STAT3 regulates NF-{κ}B recruitment to the IL-12p40 promoter in dendritic cells. Blood 105 (2005) 689-696
45. Becker C., Wirtz S., Blessing M., et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112 (2003) 693-706
46. Wannemuehler M.J., Kiyono H., Babb J.L., et al. Lipopolysaccharide (LPS) regulation of the immune response: LPS converts germfree mice to sensitivity to oral tolerance induction. J Immunol 129 (1982) 959-965
47. Walton K.L.W., Galanko J.A., Sartor R.B., et al. T cell-mediated oral tolerance is intact in germ-free mice. Clin Exp Immunol 143 (2006) 503-512
48. Cong Y., Weaver C.T., Lazenby A., et al. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol 169 (2002) 6112-6119
49. Macpherson A., Khoo U.Y., Forgacs I., et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38 (1996) 365-375
50. Barreau F., Meinzer U., Chareyre F., et al. CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLos One 2 (2007) e523
51. Watanabe T., Kitani A., Murray P.J., et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5 (2004) 800-808
52. van Beelen A.J., Zelinkova Z., Taanman-Kueter E.W., et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27 (2007) 660-669
53. Bibiloni R., Mangold M., Madsen K.L., et al. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 55 (2006) 1141-1149
54. Barnich N., and Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 23 (2007) 16-20
55. Swidsinski A., Ladhoff A., Pernthaler A., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
56. Cartun R.W., Van Kruiningen H.J., Pedersen C.A., et al. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 6 (1993) 212-219
57. Liu Y., Van Kruiningen H.J., West A.B., et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108 (1995) 1396-1404
58. Ryan P., Kelly R.G., Lee G., et al. Bacterial DNA within granulomas of patients with Crohn's disease-detection by laser capture microdissection and PCR. Am J Gastroenterol 99 (2004) 1539-1543
59. D'Haens G.R., Geboes K., Peeters M., et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114 (1998) 262-267
60. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108 (1995) 1617-1621
61. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128 (2005) 856-861
62. Darfeuille-Michaud A., Neut C., Barnich N., et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115 (1998) 1405-1413
63. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
64. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
65. Pierik M., Joossens S., Van Steen K., et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 12 (2006) 1-8
66. Hampe J., Franke A., Rosenstiel P., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn's disease in ATG16L1. Nat Genet 39 (2007) 207-211
67. Rioux J.D., Xavier R.J., Taylor K.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn's disease and implicates autophagy in disease pathogenesis. Nat Genet 39 (2007) 596-604
68. Korzenik J.R. Is Crohn's disease due to defective immunity?. Gut 56 (2007) 2-5
69. Mow W.S., Landers C.J., Steinhart A.H., et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci 49 (2004) 1280-1286
70. Duchmann R., Kaiser I., Hermann E., et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102 (1995) 448-455
71. Targan S.R., Landers C.J., Yang H., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128 (2005) 2020-2028
72. Dubinsky M.C., Lin Y.C., Dutridge D., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 101 (2006) 360-367
73. Seibold F., Brandwein S., Simpson S., et al. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 18 (1998) 153-160
74. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54 (2005) 1232-1236
75. Spivak J., Landers C.J., Vasiliauskas E.A., et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 12 (2006) 1122-1130
76. Mei L., Targan S.R., Landers C.J., et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 130 (2006) 1078-1085
77. Papadakis K.A., Yang H., Ippoliti A., et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 13 (2007) 524-530
78. Devlin S.M., Yang H., Ippoliti A., et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 132 (2007) 576-586
79. Hansen J., and Sartor R.B. Insights from animal models. In: Bernstein C.N. (Ed). IBD yearbook (2007), Remedica, London 19-55
80. Sellon R.K., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66 (1998) 5224-5231
81. Rath H.C., Herfarth H.H., Ikeda J.S., et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 98 (1996) 945-953
82. Veltkamp C., Tonkonogy S.L., de Jong Y.P., et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(ε26) mice. Gastroenterology 120 (2001) 900-913
83. Taurog J.D., Richardson J.A., Croft J.T., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180 (1994) 2359-2364
84. Schultz M., Tonkonogy S.L., Sellon R.K., et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 276 (1999) G1461-G1472
85. Bamias G., Okazawa A., Rivera-Nieves J., et al. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J Immunol 178 (2007) 1809-1818
86. Sartor R.B., Cromartie W.J., Powell D.W., et al. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 89 (1985) 587-595
87. Mourelle M., Salas A., Guarner F., et al. Stimulation of transforming growth factor β1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 114 (1998) 519-526
88. Sartor R.B., Bond T.M., and Schwab J.H. Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immun 56 (1988) 2101-2108
89. Dieleman L.A., Ridwan B.U., Tennyson G.S., et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107 (1994) 1643-1652
90. Kim S.C., Tonkonogy S.L., Albright C.A., et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128 (2005) 891-906
91. Lodes M.J., Cong Y., Elson C.O., et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 113 (2004) 1296-1306
92. Rath H.C., Wilson K.H., and Sartor R.B. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and Escherichia coli. Infect Immun 67 (1999) 2969-2974
93. Kim S.C., Tonkonogy S.L., Albright C.A., et al. Different host genetic backgrounds determine disease phenotypes induced by selective bacterial colonization. (abstr). Gastroenterology 128 (2005) A512
94. Kim S.C., Tonkonogy S.L., Karrasch T., et al. Dual association of gnotobiotic IL-10-/- mice with two nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis 13 (2007) 1457-1466
95. Hale L.P., Gottfried M.R., and Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis 11 (2005) 1060-1069
96. Yamada T., Deitch E., Specian R.D., et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 17 (1993) 641-662
97. Gardiner K.R., Erwin P.J., Anderson N.H., et al. Colonic bacteria and bacterial translocation in experimental colitis. Br J Surg 80 (1993) 512-516
98. Hobson C.H., Butt T.J., Ferry D.M., et al. Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology 94 (1988) 1006-1013
99. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 126 (2004) 1620-1633
100. Sheil B., Shanahan F., and O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr 137 (2007) S819-S824
101. Rath H.C., Schultz M., Freitag R., et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69 (2001) 2277-2285
102. Hoentjen F., Harmsen H.J., Braat H., et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin-10 gene deficient mice. Gut 52 (2003) 1721-1727
103. Chiodini R.J. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev 2 (1989) 90-117
104. Sartor R.B. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease?. Gut 54 (2005) 896-898
105. Chiodini R.J., Van Kruiningen H.J., Thayer W.R., et al. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 29 (1984) 1073-1079
106. Behr M.A., and Schurr E. Mycobacteria in Crohn's disease: a persistent hypothesis. Inflamm Bowel Dis 12 (2006) 1000-1004
107. Autschbach F., Eisold S., Hinz U., et al. High prevalence of Mycobacterium avium subsp. paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54 (2005) 944-999
108. Millar D., Ford J., Sanderson J., et al. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows' milk in England and Wales. Appl Environ Microbiol 62 (1996) 3446-3452
109. Mishina D., Katsel P., Brown S.T., et al. On the etiology of Crohn's disease. Proc Natl Acad Sci U S A 93 (1996) 9816-9820
110. Naser S.A., Schwartz D., and Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol 95 (2000) 1094-1095
111. Abubakar I., Myhill D.J., Hart A.R., et al. A case-control study of drinking water and dairy products in Crohn's disease-further investigation of the possible role of Mycobacterium avium paratuberculosis. Am J Epidemiol 165 (2007) 776-783
112. Rumsey J., Valentine J.F., and Naser S.A. Inhibition of phagosome maturation and survival of Mycobacterium avium subspecies paratuberculosis in polymorphonuclear leukocytes from Crohn's disease patients. Med Sci Monit 12 (2006) BR130-BR139
113. Bernstein C.N., Wang M.H., Sargent M., et al. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. J Clin Microbiol 45 (2007) 968-971
114. Sechi L.A., Gazouli M., Ikonomopoulos J., et al. Mycobacterium avium subsp. paratuberculosis, genetic susceptibility to Crohn's disease, and Sardinians: the way ahead. J Clin Microbiol 43 (2005) 5275-5277
115. Baumgart M., Dogan B., Rishniw M., et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 1 (2007) 403-418
116. Sechi L.A., Gazouli M., Sieswerda L.E., et al. Relationship between Crohn's disease, infection with Mycobacterium avium subspecies paratuberculosis and SLC11A1 gene polymorphisms in Sardinian patients. World J Gastroenterol 12 (2006) 7161-7164
117. Gui G.P., Thomas P.R., Tizard M.L., et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 39 (1997) 393-400
118. Selby W., Pavli P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132 (2007) 2313-2319
119. Neut C., Bulois P., Desreumaux P., et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97 (2002) 939-946
120. Darfeuille-Michaud A., Boudeau J., Bulois P., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127 (2004) 412-421
121. Glasser A.L., Boudeau J., Barnich N., et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 69 (2001) 5529-5537
122. Nuding S., Fellermann K., Wehkamp J., et al. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 56 (2007) 1240-1247
123. Barnich N., Carvalho F.A., Glasser A.L., et al. CEACAM6 acts as a receptor for adherent-invasive E coli, supporting ileal mucosa colonization in Crohn's disease. J Clin Invest 117 (2007) 1566-1574
124. Rolhion N., Barnich N., Claret L., et al. Strong decrease in invasive ability and outer membrane vesicle release in Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 with the yfgL gene deleted. J Bacteriol 187 (2005) 2286-2296
125. Boudeau J., Barnich N., and Darfeuille-Michaud A. Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol 39 (2001) 1272-1284
126. Rolhion N., Carvalho F.A., and Darfeuille-Michaud A. OmpC and the sigma(E) regulatory pathway are involved in adhesion and invasion of the Crohn's disease-associated Escherichia coli strain LF82. Mol Microbiol 63 (2007) 1684-1700
127. Simpson K.W., Dogan B., Rishniw M., et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect Immun 74 (2006) 4778-4792
128. Kotlowski R., Bernstein C.N., Sepehri S., et al. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56 (2007) 669-675
129. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007) 345-351
130. Kim H., Rhee S.H., Pothoulakis C., et al. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE(2) up-regulation of Fas ligand. Gastroenterology 133 (2007) 875-886
131. Rabizadeh S., Rhee K.J., Wu S., et al. Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis 13 (2007) 1475-1483
132. Yang P.C., Liu T., Wang B.Q., et al. Rhinosinusitis derived Staphylococcal enterotoxin B possibly associates with pathogenesis of ulcerative colitis. BMC Gastroenterol 5 (2005) 28
133. Huycke M.M., Abrams V., and Moore D.R. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23 (2002) 529-536
134. Nallapareddy S.R., Singh K.V., Sillanpaa J., et al. Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest 116 (2007) 2799-2807
135. Gophna U., Sommerfeld K., Gophna S., et al. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 44 (2006) 4136-4141
136. Manichanh C., Rigottier-Gois L., Bonnaud E., et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55 (2006) 205-211
137. Iwaya A., Iiai T., Okamoto H., et al. Change in the bacterial flora of pouchitis. Hepatogastroenterology 53 (2006) 55-59
138. Conte M.P., Schippa S., Zamboni I., et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 55 (2006) 1760-1767
139. Martinez-medina M., Aldeguer X., Gonzalez-Huix F., et al. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 12 (2006) 1136-1145
140. Swidsinski A., Weber J., Loening-Baucke V., et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43 (2005) 3380-3389
141. Kleessen B., Kroesen A.J., Buhr H.J., et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 37 (2002) 1034-1041
142. Sasaki M., Sitaraman S.V., Babbin B.A., et al. Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest (2007) In press
143. Sokol H., Lepage P., Seksik P., et al. Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. Gut 56 (2007) 152-154
144. Swidsinski A., Loening-Baucke V., Lochs H., et al. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 11 (2005) 1131-1140
145. Tsang J., Brown R.S., Andersen G.L., et al. Selective expansion of colitogenic commensal bacterial species in SPF IL-10-/- mice. (abstr). Gastroenterology 126 (2004) A291
146. Lupp C., Robertson M.L., Wickham M.E., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2 (2007) 119-129
147. Bibiloni R., Simon M.A., Albright C., et al. Analysis of the large bowel microbiota of colitic mice using PCR/DGGE. Lett Appl Microbiol 41 (2005) 45-51
148. Scanlan P.D., Shanahan F., O'Mahony C., et al. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 44 (2006) 3980-3988
149. Scupham A.J., Presley L.L., Wei B., et al. Abundant and diverse fungal microbiota in the murine intestine. Appl Environ Microbiol 72 (2006) 793-801
150. Standaert-Vitse A., Jouault T., Vandewalle P., et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 130 (2006) 1764-1775
151. Marchesi J.R., Holmes E., Khan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6 (2007) 546-551
152. Smith F.M., Coffey J.C., Kell M.R., et al. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis 7 (2005) 563-570
153. Roediger W.E., Duncan A., Kapaniris O., et al. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 104 (1993) 802-809
154. Schmidt C., Giese T., Ludwig B., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 16-23
155. Hollander D., Vadheim C.M., Brettholz E., et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105 (1986) 883-885
156. Hilsden R.J., Meddings J.B., and Sutherland L.R. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 110 (1996) 1395-1403
157. Zeissig S., Burgel N., Gunzel D., et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56 (2007) 61-72
158. Heller F., Florian P., Bojarski C., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129 (2005) 550-564
159. Madsen K.L., Malfair D., Gray D., et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 5 (1999) 262-270
160. Olson T.S., Reuter B.K., Scott K.G., et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 203 (2006) 541-552
161. Panwala C.M., Jones J.C., and Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161 (1998) 5733-5744
162. Hermiston M.L., and Gordon J.I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270 (1995) 1203-1207
163. Ho G.T., Nimmo E.R., Tenesa A., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128 (2005) 288-296
164. Rioux J.D., Daly M., Silverberg M., et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet 29 (2001) 223-228
165. van der Sluis M., De Koning B.A., De Bruijn A.C., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131 (2006) 117-129
166. Mashimo H., Wu D.C., Podolsky D.K., et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274 (1996) 262-265
167. Fellermann K., Stange D.E., Schaeffeler E., et al. A chromosome 8 gene-cluster polymorphism with low human β-defensin 2 gene copy number predisposes to Crohn's disease of the colon. Am J Hum Genet 79 (2006) 439-448
168. Hisamatsu T., Suzuki M., Reinecker H.C., et al. CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993-1000
169. Wehkamp J., Wang G., Kubler I., et al. The Paneth cell {α}-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol 179 (2007) 3109-3118
170. Xu Y., Jagannath C., Liu X.-D., et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27 (2007) 135-144
171. Marks D.J., Harbord M.W., MacAllister R., et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367 (2006) 668-678
172. Griga T., Wilkens C., Schmiegel W., et al. Association between the promoter polymorphism T/C at position -159 of the CD14 gene and anti-inflammatory therapy in patients with inflammatory bowel disease. Eur J Med Res 10 (2005) 183-186
173. Schreiter K., Hausmann M., Spoettl T., et al. Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease. Gut 54 (2005) 935-943
174. Mow W.S., Vasiliauskas E.A., Lin Y.C., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126 (2004) 414-424
175. Kraus T.A., Toy L., Chan L., et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126 (2004) 1771-1778
176. Lamhonwah A.M., Ackerley C., Onizuka R., et al. Epitope shared by functional variant of organic cation/carnitine transporter, OCTN1, Campylobacter jejuni and Mycobacterium paratuberculosis may underlie susceptibility to Crohn's disease at 5q31. Biochem Biophys Res Commun 337 (2005) 1165-1175
177. Rahbar A., Bostrom L., and Soderberg-Naucler C. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J Autoimmun 26 (2006) 155-164
178. Ebringer A., Rashid T., Tiwana H., et al. A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections. Clin Rheumatol 26 (2007) 289-297
179. Polymeros D., Bogdanos D.P., Day R., et al. Does cross-reactivity between Mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology 131 (2006) 85-96
180. Keighley M.R., Eastwood D., Ambrose N.S., et al. Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. Gastroenterology 83 (1982) 1271-1275
181. O'Boyle C.J., MacFie J., Mitchell C.J., et al. Microbiology of bacterial translocation in humans. Gut 42 (1998) 29-35
182. Ambrose N.S., Johnson M., Burdon D.W., et al. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 71 (1984) 623-625
183. Alves A., Panis Y., Bouhnik Y., et al. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 50 (2007) 331-336
184. Colombel J.F., Loftus E.V.J., Tremaine W.J., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 (2004) 878-883
185. Sands B.E., Blank M.A., Diamond R.H., et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther 23 (2006) 1127-1136
186. Colombel J.F., Loftus E.V.J., Tremaine W.J., et al. The safety profile of infliximab in clinical practice in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 12 (2004) 19-31
187. Siegel C.A., Hur C., Korzenik J.R., et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1017-1024
188. Toruner M., Loftus E.V., Colombel J.F., et al. Risk factors for opportunistic infections in inflammatory bowel diseases: a case-control study. (abstr). Gastroenterology 130 (2006) A71
189. Kane S.V., Khatibi B., and Reddy D. Higher incidence of abnormal PAP smears in women with inflammatory bowel disease. Am J Gastroenterol (2007) epub
190. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
191. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007) 339-344
192. Shen B., Goldblum J.R., Hull T.L., et al. Clostridium difficile-associated pouchitis. Dig Dis Sci 51 (2006) 2361-2364
193. Matsuoka K., Iwao Y., Mori T., et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 102 (2007) 331-337
194. Kojima T., Watanabe T., Hata K., et al. Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol 41 (2006) 706-711
195. Hedin C., Whelan K., and Lindsay J.O. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 66 (2007) 307-315
196. Floch M.H., Madsen K.K., Jenkins D.J., et al. Recommendations for probiotic use. J Clin Gastroenterol 40 (2006) 275-278
197. Rolfe V.E., Fortun P.J., Hawkey C.J., et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2006) CD004826
198. Lal S., and Steinhart A.H. Antibiotic therapy for Crohn's disease: a review. Can J Gastroenterol 20 (2006) 651-655
199. Rioux K.P., and Fedorak R.N. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 40 (2006) 260-263
200. Ohkusa T., Nomura T., Terai T., et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40 (2005) 1334-1342
201. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000) 1352-1355
202. Han W., Mercenier A., Ait-Belgnaoui A., et al. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis 12 (2006) 1044-1052
203. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., et al. The anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase (MnSOD) using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 293 (2007) G729-G738
204. Braat H., Rottiers P., Hommes D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 754-759
205. Targan S.R., and Karp L.C. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 206 (2005) 296-305
206. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
207. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
208. Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
209. Cong Y., Brandwein S.L., McCabe R.P., et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 187 (1998) 855-864
210. Liu B., Holt L., and Sartor R.B. APC regulate TH1/TH17-mediated colitis in IL-10 deficient mice. (abstr). Gastroenterology 132 (2007) A33
211. Izcue A., Coombes J.L., and Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 212 (2006) 256-271
212. Beckwith J., Cong Y., Sundberg J.P., et al. Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology 129 (2005) 1473-1484
213. Kontoyiannis D., Pasparakis M., Pizarro T.T., et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398